Reports Q3 revenue $7.73B, consensus $7.53B. "We returned to mid-single digit organic growth as we continue to execute our strategy with urgency. Our Cardiovascular and Neuroscience portfolios had strong, high-single digit organic growth as we launched new products and demonstrated continued strength in our established, market-leading Cardiac Rhythm Management and Spine franchises," said Geoff Martha, Medtronic chairman and chief executive officer. "I’m very encouraged by the rebound in our revenue growth, despite procedure volumes remaining a little softer in a few markets and volume-based procurement in China. We are confident in delivering durable revenue growth over the coming quarters as recent revenue headwinds continue to dissipate, and we drive execution across our businesses."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MDT:
- Medtronic’s (NYSE:MDT) Decent Q3 Results Kindle Hope
- Medtronic reports third quarter fiscal 2023 financial results
- Medtronic receives CE Mark for extravascular defibrillator system
- Medtronic put volume heavy and directionally bearish
- Apple names Medtronic’s Surface as Chief People Officer, Bloomberg says